And the patient voice seems to have been lost in discussions about the IRA
And a NEJM piece argues that CMS is an HTA and should start acting accordingly
And the danger of using list prices when talking obesity meds
And the White House seems to be de-emphasizing certain parts of the IRA
And a fiesty war of words in JAMA about whether ex-US value judgments can be applied stateside
And Matt Herper resurrects a good idea that is two decades old
And insurance companies are refusing to cover Leqembi
Plus ranting about AARP, and how Daniel Heider is suddenly the most interesting person in pharma
And Patients for Affordable Drugs' questionable investment in meaningless minutiae
And earnings are proving that biopharma is profiting by serving more patients, not charging more
And your semi-regular, evidence-based reminder the drug prices aren't skyrocketing
And an op-ed on the lack of patient engagement in CMS' price-setting effort
